Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWu, T.en
dc.contributor.authorTrahair, L.en
dc.contributor.authorLittle, T.en
dc.contributor.authorBound, M.en
dc.contributor.authorZhang, X.en
dc.contributor.authorWu, H.en
dc.contributor.authorSun, Z.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorRayner, C.en
dc.contributor.authorJones, K.en
dc.identifier.citationDiabetes Care, 2017; 40(5):702-705en
dc.description.abstractOBJECTIVE: To evaluate effects of vildagliptin and metformin on blood pressure (BP) and heart rate (HR) responses to intraduodenal (ID) glucose in diet-controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: Study A compared vildagliptin (50 mg) and placebo, given 60 min before a 120-min ID glucose infusion at 2 or 4 kcal/min (ID2 or ID4) in 16 patients. Study B compared metformin (850 mg) and placebo, given 30 min before ID2 over 120 min in 9 patients. RESULTS: Systolic (P = 0.002) and diastolic (P < 0.001) BP were lower and HR greater (P = 0.005) after vildagliptin compared with placebo, without interaction between vildagliptin and the glucose infusion rate. In contrast, HR was greater after metformin than placebo (P < 0.001), without any difference in systolic or diastolic BP. CONCLUSIONS: Vildagliptin reduces BP and increases HR, whereas metformin increases HR without affecting BP during ID glucose infusion in type 2 diabetes. These distinct cardiovascular profiles during enteral nutrient exposure may have implications for postprandial hypotension.en
dc.description.statementofresponsibilityTongzhi Wu, Laurence G. Trahair, Tanya J. Little, Michelle J. Bound, Xiang Zhang, Hang Wu, Zilin Sun, Michael Horowitz, Christopher K. Rayner and Karen L. Jonesen
dc.publisherAmerican Diabetes Associationen
dc.rights© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals .org/content/license.en
dc.subjectIntestine, Small; Humans; Diabetes Mellitus, Type 2; Metformin; Adamantane; Nitriles; Pyrrolidines; Glucose; Hypoglycemic Agents; Blood Pressure; Heart Rate; Postprandial Period; Aged; Female; Male; Dipeptidyl-Peptidase IV Inhibitorsen
dc.titleEffects of vildagliptin and metformin on blood pressure and heart rate responses to small intestinal glucose in type 2 diabetes.en
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidWu, T. [0000-0003-1656-9210]en
dc.identifier.orcidLittle, T. [0000-0001-9814-1036]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.